Oxbow Advisors LLC Buys Shares of 8,865 Medpace Holdings, Inc. (NASDAQ:MEDP)

Oxbow Advisors LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,865 shares of the company's stock, valued at approximately $2,701,000.

Other institutional investors have also recently made changes to their positions in the company. Jones Financial Companies Lllp raised its stake in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares during the period. Assetmark Inc. raised its stake in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares during the period. Colonial Trust Co SC raised its stake in shares of Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after buying an additional 105 shares during the period. True Wealth Design LLC raised its stake in shares of Medpace by 52.7% in the fourth quarter. True Wealth Design LLC now owns 258 shares of the company's stock worth $86,000 after buying an additional 89 shares during the period. Finally, Nemes Rush Group LLC bought a new position in shares of Medpace in the fourth quarter worth about $86,000. Institutional investors own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Robert W. Baird decreased their price objective on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. TD Cowen downgraded Medpace from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Mizuho decreased their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Truist Financial decreased their target price on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Finally, Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 target price on the stock. Twelve equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $344.82.

Medpace Price Performance

NASDAQ:MEDP opened at $323.50 on Friday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The stock's 50 day simple moving average is $305.61 and its two-hundred day simple moving average is $318.69. The company has a market cap of $9.30 billion, a price-to-earnings ratio of 24.69, a PEG ratio of 5.85 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. Medpace had a return on equity of 54.36% and a net margin of 19.31%. During the same quarter in the previous year, the business earned $3.20 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director owned 2,998 shares in the company, valued at $904,856.36. The trade was a 36.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 20.30% of the company's stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.